drugset / Trial / NCT03920722

Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis

NCT03920722 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to determine wether a rituximab-based treatment compared to standard therapy (glucocorticoid alone) in patients with microscopic polyangiitis without any bad prognosis marker increases the remission and reduces the relapse free survival rate.

Timeline

Start
2020-10-24
Primary completion
2023-09-06
Completion
2023-09-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody 1 g Intravenous